Abstract
4
CQ remains widely used against P. vivax, although treatment failures have been reported 67 (10). In Colombia, to this date there have been no reports of CQ therapeutic failure for P.
68
vivax (11). PQ is the only antimalarial commercially available to treat liver stages (12).
70
Previous studies have compared the efficacy of different PQ regimens in preventing P. 71 vivax recurrence (13). Although the standard PQ regimen (0.25 mg/kg/day for 14 days) has 72 a significant incidence of recurrence, it is the most commonly used worldwide (2). It was 73 estimated that 16.2% of patients in Colombia, treated with this regimen have at least one 74 recurrence within six months (14) . Nevertheless, the standard PQ regimen yield a lower 75 incidence of recurrences compared to regimens employing an equal total dose administered 76 for a shorter time (13, 14).
78
We conducted a prospective study in an endemic region of Colombia, to determine the All individuals diagnosed with P. vivax malaria in the diagnostic centers during the study 103 period were invited to participate. Eligibility criteria were: mono-infection with P. vivax, 104 asexual parasite count greater than 250 parasites/μl, age over 4 years, absence of general 105 danger signs or signs of severe malaria according to the criteria adopted by World Health 106 Organization (7, 9), negative pregnancy test, not breastfeeding, not reporting intake of 107 antimalarials in the preceding four weeks, residence in the study area and the ability and 108 willingness to comply with the protocol for the duration of the study. 6 maximum dose of CQ (1.5 g), while the PQ dose was adjusted for body weight.
113
Information about demographic characteristics, current disease, history of malaria, travel to 114 other endemic regions and use of preventive measures for malaria was collected.
115
Participants were monitored by thick blood smears and surveillance for symptoms on days For patients who did not meet one or more inclusion criteria, a sample of capillary blood 127 was taken before treatment but no study treatment or follow-up was provided. These 128 samples were used for malaria diagnosis and parasite genotyping; results provided 129 information for baseline parasite genetic diversity in the study area. 
194
These analyses were complemented by inferring the MLH genealogies using the Global and excluded were similar in demographic characteristics and history of malaria (Table S1 ).
224
All participants included in the recurrence surveillance had a negative malaria PCR result In Figure 4 , the monthly distribution of haplotypes detected during the study period is 264 presented. Two genetic clusters were inferred using Structure program, including the data 265 from monoclonal infections (Fig S1) , and all samples had a greater than 75% probability of 266 belonging to one of the two possible genetic clusters. A total of 87 isolates (60.4%) with 46 267 haplotypes belonged to cluster 1; while 57 isolates (39.6%) with nine haplotypes belonged 268 to cluster 2. The samples were classified into these groups to estimate haplotype 269 frequencies on Day Zero and P(match). Both clusters of P. vivax circulated simultaneously 270 in Turbo during the study period but their geographic distribution was slightly different 271 ( Fig S2) . These clusters, however, could be genetically interrelated as indicated by the 13 haplotype network (Fig S3) with the putative primary founders in the less diverse cluster 2.
273
Importantly, all MLH lineages were found in all localities so this source of bias did not 274 affect our results. Table 4 . Of a total of 29 279 recurrences, 27 were identical haplotypes to those present on Day Zero (Table 4 and Table   280 S2) to the results from the P(match) analysis for classification of recurrences indicated that were not identical. Nevertheless, the recurrence haplotypes were highly genetically related 287 to the infection episode at the time of inclusion in the study with differences at only two 288 alleles (Table S2) .
290
A group of nine participants were assigned to cluster 2 with a total of 11 recurrence events, 291 all of which were caused by haplotypes that were identical to the previous episode/s (Table   292 4). There were six recurrences by the predominant haplotype (H33), which had a very high 293 P(match), thus making it highly likely that participants were reinfected with the same 294 parasite strain that was detected on Day Zero. In this study we found that 24.1% (21/87) of P. vivax-infected participants had at least one 299 recurrence within 180 days of treatment with a standard CQ-PQ regimen, despite receiving 300 full treatment and being monitored. Additionally, 8% (7/87) of participants had three or 301 more episodes within six months. Moreover, it is highly unlikely that these recurrences 302 were recrudescence by therapeutic failure to CQ, since all participants had a negative PCR 
343
The genetic diversity of the selected markers indicates that they have enough resolution to 344 detect differences among samples of P. vivax in Turbo. 
